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Objectives
 Provide an overview on HIV 
 Review the antiretroviral classes available for the management of HIV and 
their place in therapy 
 Evaluate the new HIV treatment options 
 Differentiate between pre-exposure prophylaxis (PrEP) and post-exposure 
prophylaxis (PEP) 
 Discuss the pharmacist role in the treatment of HIV 
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HIV Overview
 HIV attacks the body’s immune system, particularly the CD4 cells which are used 
to fight off infections
 As the human body is unable to completely eradicate the virus, HIV is considered 
a life diagnosis and generally uncurable
 HIV can lead to acquired immunodeficiency syndrome (AIDS) if untreated
 With proper medical care, HIV can be controlled and patients are expected to 
have a similar life-expectancy to someone living without HIV 
 Antiretroviral therapy (ART) are medications utilized in the treatment of HIV 
 Patients are usually able to achieve an undetectable viral load by taking their ART 
as prescribed
Source: CDC- HIV Basics.
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Stages of Untreated HIV
Source: Canadian Foundation for AIDS Research. Stages of Untreated HIV Infections.
CD4+ Cells
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HIV Stages
 Stage 1: Acute Infection
 The virus invades the body’s CD4 cells and starts to replicate
 In the process of replication, the virus establishes reservoirs
 During the acute phase, the individual’s body tries to fight off the virus
 Many people experience flu-like symptoms during this stage, which occurs 
around 2-4 weeks after initial exposure
 Seroconversion occurs during this time
Source: Canadian Foundation for AIDS Research. Stages of Untreated HIV Infections.
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HIV Stages
 Stage 2: Latency Period
 Around 6 weeks following HIV infection, a stage with no signs or 
symptoms begins
 This stage is characterized by a slow reduction in CD4 cell count and 
gradual increase in HIV viral load 
 Majority of patients remain in this disease stage for around 10 years (in 
the absence of treatment) 
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Source: Canadian Foundation for AIDS Research. Stages of Untreated HIV Infections.
HIV Stages
 Stage 3: AIDS 
 Usually occurs when CD4 cell count decreases to <200 cells/mm3 or the 
patient develops an AIDS-defining condition 
 Opportunistic infections and cancers start to emerge due to depletion of 
the immune system
 Viral load once again begins to rapidly increase 
 ART prevents patients from reaching this stage 
 For patients that have been untreated and reach this stage, ART can still 
improve CD4 cell count and decrease viral load
Source: Canadian Foundation for AIDS Research. Stages of Untreated HIV Infections.
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AIDS-Defining Conditions
Source: NIH. HIV/AIDS Glossary: AIDS Case Definition.
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HIV Transmission Myths
Source: Myths About HIV and AIDS. Avert.
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HIV Transmission
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Source: Myths About HIV and AIDS. Avert.
HIV Transmission Studies
Undetectable = Untransmittable
These four studies included more than a 100,000 sex acts without condom use; yet 
there were ZERO cases of HIV transmission in partners of undetectable patients
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019. 11
HIV Transmission
Source: CDC- Vital Signs: HIV Transmission Along the Continuum of Care — United States, 2016. 12
HIV Prevalence  
Source: Epidemiology of HIV. National HIV Curriculum. 
Prevalence 
increased 
by
15%
13
HIV Incidence 
Source: Epidemiology of HIV. National HIV Curriculum. 
Incidence 
decreased 
by
13% 
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HIV Rates in the U.S.
Source: CDC- HIV in the United States by Region. 2017. 15
New Diagnosis of HIV in the U.S. 
Source: CDC- HIV Surveillance Supplemental Report Vol. 30. 2018. 
Rank Area Rate*
1 Miami – Fort Lauderdale – West Palm Beach, 
Florida 
34.4
2 Atlanta – Sandy Springs – Roswell, Georgia 28.5
3 Memphis, Tennessee 27.8
4 Baton Rouge, Louisiana 27.5
5 Orlando – Kissimmee – Sanford, Florida 27.3
6 New Orleans – Metairie, Louisiana 24.6 
7 Jackson, Mississippi 23.6
8 Augusta – Richmond County, Georgia 23.5
9 Jacksonville, Florida 21.2
10 Houston – The Woodlands – Sugar Land, Texas 20.6
*Rates are per 100,000 people
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New HIV Diagnosis among MSM
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
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MSM: Men who have sex with men
Source: CDC- HIV Incidence: Estimated Annual Infections in the U.S., 2010-2016.
Incidence of HIV among Latinos and African American MSM ages 
25-34 from 2010 to 2016
New HIV Diagnosis among MSM
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Types of HIV Tests
Source: HIV i-Base. Different Types of HIV tests.
Type of Test What does the test detect? 
RNA/DNA Antigen Antibody
PCR/viral load X
p24 test X
4th generation test X X
1st/2nd/3rd generation tests X
Rapid test: finger prick and oral swab 
(ex: OraQuick)
X
Western blot tests X
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Time to HIV Antigen and 
Antibody Detection
Source: HIV RNA Test. HIV RNA Test for HIV Early Detection. 20
Rapid ART Initiation
 ART should be initiated as soon as possible
 Immediate ART treatment has been shown to reduce both AIDS and non-
AIDS related events
 There is no increase in adverse events with immediate versus delayed ART
Source: Rapid ART Initiation. Clinical Guidelines Program. New York State Department of Health AIDS Institute.
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HIV Life Cycle 
Source: NIH: AIDSinfo – The HIV Life Cycle. 
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HIV Treatment
 An ART regimen for a treatment-naive patient generally consists of 
two nucleoside reverse transcriptase inhibitors (NRTIs) plus a 3rd
active drug from one of the following classes: 
• Integrase strand transfer inhibitors (INSTI) 
• Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
• Protease inhibitors (PI) 
 Currently, the Department of Health and Human Services (DHHS) 
guidelines recommend INSTI-based regimens for most ART-naive 
patients
Source: US DHHS. Guidelines for Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2019.
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First-Line Treatment
*Tenofovir formulation can be either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide 
(TAF) 
Brand Recommended Initial Regimen
Biktarvy® Bictegravir/tenofovir alafenamide/emtricitabine
Dovato® Dolutegravir/lamivudine
(Except for patients with HIV RNA >500,000 copies/mL or 
with hepatitis B co-infection) 
Triumeq® Dolutegravir/abacavir/lamivudine
(Except for patients who are HLA-B*5701 positive or 
with hepatitis B co-infection)
Tivicay® and
Truvada® or Descovy®
Dolutegravir plus tenofovir*/emtricitabine
Isentress® and
Truvada® or Descovy®
Raltegravir plus tenofovir*/emtricitabine
Source: US DHHS. Guidelines for Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2019.
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TAF versus TDF 
TAF TDF
Efficacy Comparable Comparable
Renal toxicity 
risk 
Bone density 
decrease risk 
Weight gain
Source: The Lancet. 2015; 385(9987): 2606-2615. 25
INSTI-Based Regimen Selection
Factors that influence the choice of INSTI regimen in treatment-naive patients:
Agent Advantages Disadvantages
Dolutegravir • Few drug interactions
• Single-tablet formulation
• Higher barrier to resistance
• Preferred ARV in pregnancy
• Can be used for rapid ART start
• Co-formulated with abacavir and 
lamivudine
Bictegravir • Few drug interactions
• Single-tablet formulation
• Higher barrier to resistance
• Can be used for rapid ART start
• Lack of data in pregnancy 
Raltegravir • Few drug interactions
• Available as daily dosing
• Preferred ARV in pregnancy
• Not available as a single-tablet 
formulation
• Lower barrier to resistance
• Twice daily option 
Elvitegravir • Single-tablet formulation 
• Can be used for rapid ART start
• Lower barrier to resistance
• Avoid in pregnancy due to 
inadequate drug concentrations in 
the 2nd/3rd trimesters
Sources: US DHHS. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents. 2019.
Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
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Abacavir Hypersensitivity 
Reaction 
 Black box warning: 2-9% incidence of hypersensitivity reaction 
• Caucasian > African American > Latino > Asian 
 HLA-B*5701 testing should precede the use of abacavir
• Record positive result as a true allergy 
 Patients should be counseled on signs and symptoms of abacavir
hypersensitivity, which include: 
• Fever, rash, nausea/vomiting, flu-like symptoms
• Onset is 4-6 weeks with a median of 9 days
Source: Clinical Infectious Diseases. 2002; 34(8): 1137–1142. 27
True/False Question
 The initial antiretroviral regimen recommended for 
most treatment-naive patients consists of two 
NRTIs and a boosted PI
28
True/False Question
 The initial antiretroviral regimen recommended for 
most treatment-naive patients consists of two 
NRTIs and a boosted PI –False!
o The initial antiretroviral regimen for a treatment-naive patient 
usually consists of two NRTIs plus an INSTI
Answer
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Complete Two-Drug ART
 Dovato® is now recommended for treatment-naive patients first-line
 There are considerations as to whom should be taking this medication
• Still not recommended for certain patient populations
• Adherence is extremely important 
• Good for patients that cannot use abacavir,  TDF, or TAF
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
GEMINI 1&2 Trial Results
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Complete Two-Drug ART
 Juluca® (dolutegravir/rilpivirine) is FDA-approved for HIV treatment in 
select patients
 Considerations for this medication include: 
• Not recommended for treatment-naive patients
• Approved for use in patients that are virologically suppressed ≥ 6 months 
on a stable regimen with no treatment failure and no resistance mutations
• Adherence is very important
• Rilpivirine requires food for optimal absorption
• Patients should not use proton pump inhibitors
Source: Lancet HIV. 2019; 6(9): e576-e587. 31
True/False Question
Dovato® is the first FDA-approved 
complete two-drug regimen for treatment-
naive HIV-infected patients
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True/False Question
Dovato® is the first FDA-approved 
complete two-drug regimen for treatment-
naive HIV-infected patients–True!
o Dovato® components include dolutegravir and 
lamivudine 
Answer
33
HIV Comorbidities
 Evaluate the patient as a whole when initiating ART treatment 
 Most common comorbidities in people living with HIV include:
• Hypertension: 25-65%
• Hyperlipidemia: 22-48%
• Diabetes: 9-31%
• Renal impairment: 5-20%
• Cardiovascular (CV) events: 3-16%
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
The Journal of Infectious Diseases. 2017;  216(12): 1481–1483. 34
HIV Treatment
ART to avoid in patients with select comorbidities: 
Condition Consider Avoiding Rationale
Chronic Kidney Disease 
(CrCl ≤ 59 mL/min)
TDF
Exception: ESRD
Risk of nephrotoxicity
Osteoporosis TDF Risk of decreasing bone mineral 
density 
Severe Liver Disease Abacavir, nevirapine, atazanavir, darunavir, 
elvitegravir
Risk of increasing liver enzymes
Psychiatric Disorders Efavirenz, rilpivirine Risk of exacerbating psychiatric
behaviors and/or increasing 
suicide risk 
Cardiovascular Risk Abacavir, lopinavir/ritonavir Increased CV risk observed in 
studies
Dyslipidemia Boosted protease inhibitors, efavirenz, 
elvitegravir/cobicistat, TDF
Risk of hyperlipidemia
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
CrCl: Creatinine clearance
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Opportunistic Infection Prophylaxis
Pneumocystis jiroveci Pneumonia (PJP)
Indication for 
initiation
1. CD4 count < 200 cells/mm3 or
2. CD4 percentage < 14% or
3. CD4 count 200-250 cells/mm3 with delayed initiation of ART and 
frequent CD4 count monitoring not possible
Prophylaxis Preferred therapy:
• TMP/SMX DS or SS daily
Alternative therapy:
• TMP/SMX DS three times per week
• Dapsone 100 mg daily or dapsone 50 mg twice daily
• Atovaquone 1,500 mg daily
• Aerosolized pentamidine 300 mg (nebulizer) every month
Indication for 
discontinuation
• CD4 count ≥ 200 cells/mm3 for ≥ 3 months in response to ART 
• CD4 count between 100-200 cells/mm3 and HIV RNA undetectable for 
≥ 3 months 
TMP/SMX: Sulfamethoxazole/ Trimethoprim 
DS: Double strength; SS: Single strength  
Source: US DHHS. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2019.
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Opportunistic Infection Prophylaxis
Toxoplasma gondii Encephalitis
Indication for 
initiation
1. CD4 count < 100 cells/mm3 and Toxoplasma IgG positive 
Prophylaxis Preferred therapy:
• TMP/SMX DS daily
Alternative therapy:
• TMP/SMX DS three times per week 
• TMP/SMX SS daily
• Atovaquone 1,500 mg daily 
Indication for 
discontinuation
• CD4 count ≥ 200 cells/mm3 for ≥ 3 months in response to ART 
• CD4 count between 100-200 cells/mm3 and HIV RNA undetectable for 
≥ 3 months
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Source: US DHHS. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2019.
Opportunistic Infection Prophylaxis
Mycobacterium avium complex (MAC)
Indication for 
initiation
Primary prophylaxis is not recommended for adults and adolescents 
who immediately initiate ART
1. CD4 count < 50 cells/mm3 not on fully suppressive ART
Prophylaxis Preferred therapy:
• Azithromycin 1,200 mg once weekly 
• Azithromycin 600 mg twice weekly
• Clarithromycin 500 mg twice daily 
Alternative therapy:
• Rifabutin 300 mg daily
Indication for 
discontinuation
• Initiation on effective ART 
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Source: US DHHS. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2019.
PrEP versus PEP
 PrEP and PEP are methods for preventing HIV infection that involve taking HIV medications
 PreP and PEP are for people who do not have HIV but are at risk of acquiring it
Source: NIH: AIDSinfo – PrEP vs PEP and World Health Organization: Post-exposure prophylaxis to prevent HIV infection. 2014. 
PrEP PEP
When is it taken? Before HIV exposure After HIV exposure, should be taken 
within 72 hours after possible 
exposure
Who is it for? For people that are HIV-negative and: 
• Have sex with an HIV-positive 
partner
• Have multiple partners or partner(s) 
with unknown HIV status
• Share injection drug equipment
For people that are HIV-negative but 
may have been exposed through:
• Sexual intercourse 
• Needle-stick injury
• Sharing injection drug equipment
• Sexual assault
How effective is it? If used as directed, can reduce HIV risk 
from:
• Sexual intercourse by 99%
• Injection drug use by at least 74% 
PEP effectiveness decreases as time 
passes after exposure, but if started 
soon after exposure, it can reduce 
HIV risk by more than 80%
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PrEP
Only 90,000 PrEP prescriptions were filled in 2015
Source: CDC – HIV Prevention Pill Not Reaching Most Americans Who Could Benefit. 40
PrEP
Source: CDC – 2018 Conference on Retroviruses and Opportunistic Infections. 41
PrEP
 As of December 2019, there are two FDA-approved medications that can 
be utilized for PrEP
• Truvada® (TDF plus emtricitabine)
• Descovy® (TAF plus emtricitabine) 
 There are other options currently being tested for PrEP
• Long acting injectable (late phase development)
• Long acting implantable (early phase development)
• Topical/local approach (early phase development) 
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019. 42
Why is PrEP important? 
Source: 22nd International AIDS Conference. Amsterdam, Netherlands. 2018. 
2012 2013 2014 2015 2016
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PrEP is 99% effective in reducing 
the risk of acquiring HIV through 
sexual contact
True/False Question
44
PrEP is 99% effective in reducing 
the risk of acquiring HIV through 
sexual contact –True!
True/False Question
Answer
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PEP
Duration: Taken for 28 days 
Age Group Preferred/
Alternative
Medication
Adults, adolescents ≥ 13 
years of age, or pregnant 
women with normal 
renal function (CrCl
≥ 60 mL/min)
Preferred
Emtricitabine/tenofovir once daily with either: 
• Raltegravir 400 mg twice daily or dolutegravir 50 mg once daily
Alternative
Emtricitabine/tenofovir once daily with both: 
• Darunavir 800 mg once daily and ritonavir 100 mg once daily
Adults, adolescents ≥ 13 
years of age, or pregnant 
women with renal 
dysfunction (CrCl ≤ 59 
mL/min)
Preferred
Lamivudine/zidovudine once daily (renally adjusted) with either:  
• Raltegravir 400 mg twice daily or dolutegravir 50 mg once daily
Alternative Lamivudine/zidovudine once daily (renally adjusted) with both: 
• Darunavir 800 mg once daily and ritonavir 100 mg once daily
Source: Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV. 2016.
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Pharmacist Role
 Counseling
• Adherence 
• Common and severe side effects
• Time to undetectable viral load
 Supportive treatment 
• Serve as a liaison to provide the most appropriate treatment to patients
 Therapy recommendation
• Support the patients and encourage them to advocate for themselves
• Contact prescribers and inform them about possible side effects 
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019.
Journal of Acquired Immune Deficiency Syndrome. 2011; 58(2): 181-187.
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Tools to Assist with Adherence
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019. 48
Conclusion
 New and groundbreaking ART options keep emerging 
 Populations such as MSM are still at risk
 Novel and simpler therapies are being integrated into the guidelines 
 Pharmacists can have a significant impact on HIV treatment 
• Linkage to care 
• Counseling 
• Selection and optimization of ART
• Management of concurrent disease states 
Source: Insights and Developments in HIV Treatment Strategies. Presentation. Las Vegas, NV. 2019. 49
Questions?
50
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